View More Recent Stories

Nov 12, 2024 07:31AM Ocular Therapeutix (OCUL) Appoints Namrata Saroj, OD, as Chief Business Officer

Oct 16, 2024 06:54AM H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)

Oct 15, 2024 07:31AM Ocular Therapeutix (OCUL) Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI in Wet AMD

Sep 19, 2024 07:40AM Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)

Sep 3, 2024 08:06AM Ocular Therapeutix (OCUL) Appoints Donald Notman as COO

Aug 7, 2024 07:14AM Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c

Aug 7, 2024 07:02AM Ocular Therapeutix (OCUL) Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

Jul 17, 2024 07:56AM Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)

Jul 12, 2024 08:18AM Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)

Jun 27, 2024 09:31AM Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)

Jun 20, 2024 06:48AM TD Cowen Upgrades Ocular Therapeutix (OCUL) to Buy

Jun 14, 2024 03:13PM JMP Securities Reiterates Market Outperform Rating on Ocular Therapeutix (OCUL)

Jun 14, 2024 07:57AM H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)

Jun 14, 2024 07:47AM TD Cowen Reiterates Hold Rating on Ocular Therapeutix (OCUL)

View More Recent Stories